Latest & greatest articles for osteoarthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoarthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoarthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoarthritis

441. Strength training for treatment of osteoarthritis of the knee: a systematic review

Strength training for treatment of osteoarthritis of the knee: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

442. Does the hip powder of Rosa canina (rosehip) reduce pain in osteoarthritis patients: a meta-analysis of randomized controlled trials

Does the hip powder of Rosa canina (rosehip) reduce pain in osteoarthritis patients: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

443. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

-inflammatory drugs (NSAIDs) (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis (OA) and rheumatoid arthritis (RA). Authors' conclusions The COX-2 selective NSAIDs examined were found to be similar to non-selective NSAIDs for the symptomatic relief of RA and OA and to provide superior GI tolerability (the majority of evidence is in patients with OA). Although COX-2 selective NSAIDs offer protection against serious GI events, the amount of evidence (...) Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Cyclooxygenase-2

2008 Health Technology Assessment (HTA) Database.

444. Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis

Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

445. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in The Netherlands Full Text available with Trip Pro

Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in The Netherlands Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in The Netherlands Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in The Netherlands Al MJ, Maniadakis N, Grijseels EW, Janssen M Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to compare the costs and upper gastrointestinal side effects of six treatments for patients with rheumatoid arthritis and osteoarthritis. Arthrotec was the most cost-effective strategy for all and for medium-to-high risk patients, while celecoxib

2008 NHS Economic Evaluation Database.

446. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: A randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. (Abstract)

The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: A randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. OBJECTIVE: To determine whether the efficacy of diacerein persists at 2 months after the end of a 3-month treatment period, compared with placebo, in patients with painful knee osteoarthritis (OA). METHODS: After a 1-week nonsteroidal antiinflammatory (...) drug washout period, patients received either diacerein or placebo for 3 months, followed by an off-treatment period of 3 months to determine the carryover effects of the drug. Although patients were followed up through month 6, the primary efficacy end point was the percent change from baseline in pain (Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC] A) at month 5 (i.e., 2 months after the end of treatment) compared with placebo. The co-primary efficacy end point

2008 EvidenceUpdates Controlled trial quality: predicted high

447. Osteoarthritis of the knees.

Osteoarthritis of the knees. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline Clearinghouse (NGC) has ended

2008 Singapore Ministry of Health

448. Class Act: Is there clinical evidence for the use of chondroitin sulfate in the treatment of osteoarthritis?

Class Act: Is there clinical evidence for the use of chondroitin sulfate in the treatment of osteoarthritis? Class Act: Is there clinical evidence for the use of chondroitin sulfate in the treatment of osteoarthritis? – Clinical Correlations Search Class Act: Is there clinical evidence for the use of chondroitin sulfate in the treatment of osteoarthritis? October 17, 2008 4 min read | | Sites We Follow: Useful Links: Questions? Comments? Contact us! © New York University. All rights reserved

2008 Clinical Correlations

449. Effectiveness of medial-wedge insole treatment for valgus knee osteoarthritis Full Text available with Trip Pro

Effectiveness of medial-wedge insole treatment for valgus knee osteoarthritis To assess the efficacy of medial-wedge insoles in valgus knee osteoarthritis (OA).Thirty consecutive women with valgus-deformity knee OA > or = 8 degrees were randomized into 2 groups: medial insole (insoles with 8-mm medial elevation at the rearfoot [n = 16]) and neutral insole (similar insole without elevation [n = 14]). Both groups also wore ankle supports. A blinded examiner assessed pain on movement, at rest (...) , and at night with a visual analog scale (VAS), the Lequesne index, and Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index. Femorotibial, talocalcaneal, and talar tilt angles were evaluated at baseline and after 8 weeks of insole use.Significant reductions in the medial insole group were observed for pain on movement (mean +/- SD VAS pre- and postintervention 8.1 +/- 1.5 versus 4.2 +/- 2.4; P = 0.001), at rest (5.1 +/- 2.3 versus 2.7 +/- 2.4; P = 0.002), and at night (6.1 +/- 2.7 versus

2008 EvidenceUpdates Controlled trial quality: uncertain

450. Glucosamine and chondroitin sulphate did not improve pain in osteoarthritis of the knee

Glucosamine and chondroitin sulphate did not improve pain in osteoarthritis of the knee Glucosamine and chondroitin sulphate did not improve pain in osteoarthritis of the knee | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Glucosamine and chondroitin sulphate did not improve pain in osteoarthritis of the knee Article Text Therapeutics Glucosamine and chondroitin sulphate did not improve pain in osteoarthritis of the knee Statistics from

2007 Evidence-Based Medicine

451. WITHDRAWN: Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. (Abstract)

WITHDRAWN: Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. Non-steroidal anti-inflammatory drugs (NSAIDs) have been widely used as a pharmacologic treatment to relieve pain for patients with OA of the hip. However, these agents are associated with significant toxicity, particularly in the elderly population (age > 65 years).To review all randomized trials of analgesics and anti-inflammatory therapy in osteoarthritis (OA) of the hip. To determine (...) which non-steroidal, anti-inflammatory drug (NSAID) is the most effective, and which NSAID is the most toxic.We searched the Cochrane Musculoskeletal Group's trials register, the Cochrane Controlled Trials Register and MEDLINE up to August 1994. Reference lists of all trials were also manually searched.All randomized controlled trials comparing non-steroidal anti-inflammatory drugs (NSAIDs) and/or analgesics in patients with Osteoarthritis. The trials selected for inclusion were identified by one

2007 Cochrane

452. WITHDRAWN: Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee. Full Text available with Trip Pro

WITHDRAWN: Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee. Osteoarthritis(OA) is the most common rheumatic disease. Simple analgesics are now accepted as the appropriate first line pharmacological treatment of uncomplicated OA. Non-aspirin NSAIDs are licensed for the relief of pain and inflammation arising from rheumatic disease.To determine whether there is a difference in the relative efficacy of individual non-steroidal anti-inflammatory drugs (...) (NSAIDs) when used in the management of osteoarthritis (OA) of the knee.We searched Medline (1966-1995) and Bids Embase (Jan-Dec, 1980-1995). The searches were limited to publications in the English language, and were last performed in November 1996. We used modified Cochrane Collaboration search strategy to identify all randomised controlled trials. The MeSH heading "osteoarthritis" was combined with the generic names of the 17 non-aspirin NSAIDs licensed in the UK for the management of OA in general

2007 Cochrane

453. WITHDRAWN: Low level laser therapy (Classes III) for treating osteoarthritis. Full Text available with Trip Pro

in the treatment of OA.To assess the effectiveness of class III LLLT for osteoarthritis when irradiation is directed at the osteoarthritic joint capsule.Searches were conducted in the following databases: MEDLINE, EMBASE, the Cochrane Musculoskeletal registry, the Rehabilitation and Related Therapies field registry and the Cochrane Controlled Trials Register up to May, 2005.Following an a prior protocol, only controlled clinical trials of LLLT for the treatment of patients with a clinical diagnosis of OA were (...) significant difference in favor of laser treatment for patient-assessed global disease activity with laser compared to placebo (RR 1.70, 95%CI: 1.1. to 2.63). One trial evaluated the effectiveness of laser treatment in temporomandibular joint OA and found a statistically significant difference (WMD 38.69, 95% CI: 29.25 to 48.13) using the change in VAS score to measure pain. One study found a statistically significant difference in favor of laser treatment at the end of treatment and at 4 and 8 weeks post

2007 Cochrane

454. Review: viscosupplementation for knee osteoarthritis reduces pain and improves function Full Text available with Trip Pro

Review: viscosupplementation for knee osteoarthritis reduces pain and improves function Review: viscosupplementation for knee osteoarthritis reduces pain and improves function | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: viscosupplementation for knee osteoarthritis reduces pain and improves function Article Text Therapeutics Review: viscosupplementation for knee osteoarthritis reduces pain and improves function Statistics from

2007 Evidence-Based Medicine

455. Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis (IPG230)

in conjunction with the clinical guideline. Description Osteoarthritis of the knee can cause pain, stiffness, swelling and difficulty in walking. An arthroscopic knee washout involves flushing the joint with fluid, which is introduced through small incisions in the knee. The procedure is often done with debridement, which is the removal of loose debris around the joint. and for this guidance. Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence (...) Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis (IPG230) Overview | Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis | Guidance | NICE Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis Interventional procedures guidance [IPG230] Published date: August 2007 Share Save Guidance The National Institute for Health and Clinical Excellence (NICE) has issued full guidance

2007 National Institute for Health and Clinical Excellence - Interventional Procedures

456. Acupuncture as an adjunct to exercise based physiotherapy for osteoarthritis of the knee: randomised controlled trial. Full Text available with Trip Pro

Acupuncture as an adjunct to exercise based physiotherapy for osteoarthritis of the knee: randomised controlled trial. To investigate the benefit of adding acupuncture to a course of advice and exercise delivered by physiotherapists for pain reduction in patients with osteoarthritis of the knee.Multicentre, randomised controlled trial.37 physiotherapy centres accepting primary care patients referred from general practitioners in the Midlands, United Kingdom.352 adults aged 50 or more (...) with a clinical diagnosis of knee osteoarthritis.Advice and exercise (n=116), advice and exercise plus true acupuncture (n=117), and advice and exercise plus non-penetrating acupuncture (n=119).The primary outcome was change in scores on the Western Ontario and McMaster Universities osteoarthritis index pain subscale at six months. Secondary outcomes included function, pain intensity, and unpleasantness of pain at two weeks, six weeks, six months, and 12 months.Follow-up rate at six months was 94%. The mean

2007 BMJ Controlled trial quality: predicted high

457. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone Full Text available with Trip Pro

Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release (...) delivery System hydromorphone compared with an equally analgesic dose of extended-release oxycodone, administered two or three times a day, in patients with chronic osteoarthritis and severe pain. The hydromorphone was a cost-effective alternative to oxycodone from the perspective of the German health insurance system. The study used validated methodology, with a clear presentation of data sources. The authors’ conclusions are likely to be valid and robust. Type of economic evaluation Cost-utility

2007 NHS Economic Evaluation Database.

458. Treatment of primary and secondary osteoarthritis of the knee

CJ, Ziegler KM, Aronson N.. Treatment of primary and secondary osteoarthritis of the knee. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 157. 2007 Authors' objectives "Systematic review of outcomes of three treatments for osteoarthritis (OA) of the knee: intra-articular viscosupplementation; oral glucosamine, chondroitin or the combination; and arthroscopic lavage or debridement." (Structured abstract) Authors' conclusions Osteoarthritis (...) Treatment of primary and secondary osteoarthritis of the knee Treatment of primary and secondary osteoarthritis of the knee Treatment of primary and secondary osteoarthritis of the knee Samson DJ, Grant MD, Ratko TA, Bonnell CJ, Ziegler KM, Aronson N. Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Samson DJ, Grant MD, Ratko TA, Bonnell

2007 Health Technology Assessment (HTA) Database.

459. Viscosupplementation for the treatment of osteoarthritis of the knee

justifi ed to contemplate public funding for viscosupplementation for patients with knee OA in Quebec. However, this treatment could be offered to some people, who would meet strict eligibility criteria similar to those adopted by other third-party payers presented in this report. Project page URL INAHTA brief and checklist Indexing Status Subject indexing assigned by CRD MeSH Osteoarthritis, Knee /therapy Language Published French Country of organisation Canada Province or state Quebec English (...) Viscosupplementation for the treatment of osteoarthritis of the knee Viscosupplementation for the treatment of osteoarthritis of the knee Viscosupplementation for the treatment of osteoarthritis of the knee Dagenais P, Framarin A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Dagenais P, Framarin A. Viscosupplementation for the treatment

2007 Health Technology Assessment (HTA) Database.

460. An economic model of long-term use of celecoxib in patients with osteoarthritis Full Text available with Trip Pro

An economic model of long-term use of celecoxib in patients with osteoarthritis An economic model of long-term use of celecoxib in patients with osteoarthritis An economic model of long-term use of celecoxib in patients with osteoarthritis Loyd M, Rublee D, Jacobs P Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Loyd M, Rublee D, Jacobs P. An economic model of long-term use of celecoxib in patients with osteoarthritis. BMC (...) ; Osteoarthritis /diagnosis /drug therapy /economics; Probability; Pyrazoles /economics /therapeutic use; Quality-Adjusted Life Years; Risk Factors; Sensitivity and Specificity; Severity of Illness Index; Sulfonamides /economics /therapeutic use AccessionNumber 22007001888 Date bibliographic record published 23/12/2008 Date abstract record published 29/04/2009 NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019 University of York Homepage Options

2007 NHS Economic Evaluation Database.